Lyrica

Lyrica is a brand name of pregabalin, approved by the FDA in the following formulation(s):

LYRICA (pregabalin - capsule; oral)

• 
  Manufacturer: PF PRISM
  
  Approval date: December 30, 2004
  
  Strength(s): 100MG, 150MG, 200MG, 225MG, 25MG, 300MG ^[RLD], 50MG, 75MG
  

LYRICA (pregabalin - solution; oral)

• 
  Manufacturer: PF PRISM
  
  Approval date: January 4, 2010
  
  Strength(s): 20MG/ML ^[RLD]

Has a generic version of Lyrica been approved?

No. There is currently no therapeutically equivalent version of Lyrica available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lyrica. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  GABA and L-glutamic acid analogs for antiseizure treatment
  Patent 5,563,175
  Issued: October 8, 1996
  Inventor(s): Silverman; Richard B. & Andruszkiewicz; Ryszard & Yuen; Po-Wai & Sobieray; Denis M. & Franklin; Lloyd C. & Schwindt; Mark A.
  Assignee(s): Northwestern University
  Warner-Lambert Company
  A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
  
  Patent expiration dates:
  
  
  • October 8, 2013
    
    ✓ 
    Patent use: TREATMENT OF SEIZURE DISORDER
  
  



• 
  Isobutylgaba and its derivatives for the treatment of pain
  Patent 6,001,876
  Issued: December 14, 1999
  Inventor(s): Singh; Lakhbir
  Assignee(s): Warner-Lambert Company
  The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
  
  Patent expiration dates:
  
  
  • December 30, 2018
    
    ✓ 
    Patent use: MANAGEMENT OF FIBROMYALGIA
  
  
  
  • December 30, 2018
    
    ✓ 
    Patent use: TREATMENT OF PAIN
  
  



• 
  Gamma amino butyric acid analogs and optical isomers
  Patent 6,197,819
  Issued: March 6, 2001
  Inventor(s): Silverman; Richard B. & Andruszkiewicz; Ryszard
  Assignee(s): Northwestern University
  A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
  
  Patent expiration dates:
  
  
  • December 30, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Isobutylgaba and its derivatives for the treatment of pain
  Patent RE41920
  Issued: November 9, 2010
  Inventor(s): Singh; Lakhbir
  Assignee(s): Warner-Lambert Company LLC
  The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
  
  Patent expiration dates:
  
  
  • December 30, 2018
    
    ✓ 
    Patent use: TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
  
  

See also...

• Lyrica Consumer Information (Drugs.com)
• Lyrica Consumer Information (Wolters Kluwer)
• Lyrica Consumer Information (Cerner Multum)
• Lyrica Advanced Consumer Information (Micromedex)
• Lyrica AHFS DI Monographs (ASHP)
• Pregabalin Consumer Information (Wolters Kluwer)
• Pregabalin Consumer Information (Cerner Multum)
• Pregabalin Advanced Consumer Information (Micromedex)
• Pregabalin AHFS DI Monographs (ASHP)